Canopy Growth Faces a Defining Quarter as Refinancing Costs Meet Narrowing Losses

Canopy Growth slashed net loss 68% YoY, revenue up 13% to C$81.2M, but new US$150M debt and flat stock raise concerns.

The arithmetic of Canopy Growth's turnaround is getting simpler to follow, even if the stock price refuses to cooperate. The Canadian cannabis producer cut its net loss by 68 percent year-over-year in the first fiscal quarter, while revenue climbed 13 percent to 81.2 million CAD — growth that spanned every business segment for the first time under CEO Luc Mongeau's leadership.

Yet the shares trade at 0.8528 euros, barely 1.4 percent above their 50-day moving average and roughly 57 percent below the 52-week high of 2.00 euros. The market's indifference to the operational progress stems from a more complicated story unfolding on the balance sheet, where a new 150-million-US-dollar secured credit facility has replaced the company's previous first-lien lending arrangement.

That refinancing, completed alongside the acquisition of MTL Cannabis in March, represents a structural shift in how Canopy Growth funds its operations. The critical question for investors is whether the new debt burden will consume the margin improvements the company has worked so hard to achieve — or whether the streamlined cost base can absorb the interest payments while growth continues.

The early signs are encouraging. Adjusted EBITDA losses narrowed to 3.2 million CAD, and management maintains its target of reaching positive adjusted EBITDA during fiscal 2027. The loss reduction stems from cost-cutting measures initiated at the end of the prior fiscal year, including targeted workforce reductions and tighter general and administrative spending. Some of the remaining sales and administration expenses reflect the ongoing integration of MTL Cannabis, a deal that positions Canopy Growth as a leading medical cannabis platform in its home market.

The company's international ambitions received a boost in mid-August when regulators in Tübingen renewed the EU-GMP certification for its Kincardine production facility. That approval preserves Canopy Growth's access to European medical cannabis markets, where international revenue grew 10 percent in the quarter and margins tend to run higher than in the North American recreational segment.

Investor attention now shifts to September 25, when the company holds its annual general meeting. The annual report and related materials were distributed to shareholders in mid-August, and the gathering offers management a platform to make the case that the restructuring is gaining traction.

The bearish counterargument is not difficult to construct. The stock has fallen 41 percent over the past twelve months, and the new secured debt obligates future cash flows to interest and principal payments regardless of whether revenue growth persists. With annualized 30-day volatility running at 48 percent, the market continues to price in substantial uncertainty about whether the balance-sheet overhaul is complete or merely a work in progress.

The stock sits 14 percent above its 52-week low of 0.7500 euros, leaving room for a recovery rally if the next quarterly report validates the refinancing strategy. But if interest costs begin to outpace operational improvements, or if the MTL integration hits snags, the financing burden could quickly outweigh the progress made on the income statement.

The upcoming quarterly report will provide the first real test of whether the new capital structure translates into more stable margins — or whether the cost of the turnaround eats into the growth that the company has worked so hard to deliver.